Project portfolio 2
RespiriTB RespiriNTM


Mtr target exploration.

Boosting Ethionamide efficacy and lowering the dose with small molecule transcriptional modulators to overcome MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

Demonstrating penetration of gepotidacin in tonsillar and prostate tissues.

Molecule targeting cholesterol catabolism of mycobacteria.

Compound targeting Mycobacterium tuberculosis tryptophan synthase, enzyme that catalyses the final two steps in the biosynthesis of tryptophan.

Compounds targeting energy metabolism (electron chain transport).

Compound targeting LysS (lysine tRNA synthase), which is an essential gene as assessed by transposon mutagenesis.

Mmpl3 compounds with potent in vitro inhibitory and bactericidal activity against M tuberculosis.

Natural product analogs active against M.tb

Piperazinobenzothiazinone derivative as anti-mycobacterial compound that targets and covalently inhibits the enzyme DprE1.

Lead optimization program on BC1 inhibitors.

Mtr target exploration.


Progress novel assets (one FIH start) for Non-Tubercular Mycobacterium (NTM) that may act synergistically with Bedaquiline and cytochrome bc Drugs.